Effect of renal replacement therapy on cellular cytokine production in patients with renal disease  by Kimmel, Paul L. et al.
Kidney International, Vol. 38 (1990), pp. 129—135
Effect of renal replacement therapy on cellular cytokine
production in patients with renal disease
PAUL L. KIMMEL, TERENCE M. PHILLIPs, ELIZABETH PHILLIPs, and JUAN P. BOSCH
Department of Medicine, Rita Gusack Laboratory, Division of Renal Diseases and Hypertension, and the Biostatistics Center, George
Washington University Medical Center, Washington, D.C., USA
Effect of renal replacement therapy on cellular cytokine production in
patients with renal disease. To evaluate the effect of renal replacement
therapy on cellular cytokine production in patients with renal disease,
we studied interleukin I (IL-I) and interleukin-2 (IL-2) production by
target cells stimulated with supernatants from cultured peripheral blood
mononuclear cells from patients with end-stage renal disease, who were
treated with hemodialysis and continuous ambulatory peritoneal dialy-
sis (CAPD) before and after hemodialysis or a peritoneal dialysate
exchange, compared to normal subjects used as time controls, and
patients with chronic renal insufficiency. initial cellular IL-2 production
was increased in patients with hemodialysis, compared to normal
controls. The ratio of pretreatment cellular IL-2 and IL-l production
was increased in all patient groups compared to normal subjects, Both
hemodialysis and CAPD treatments resulted in increased cellular IL-i(51.7%, P < 0.007, and 42.8%, P < 0.002, respectively) and IL-2
production (50.5%, P < 0.015, and 33.3%, P < 0.0008, respectively).
The hemodialysis group had significantly higher cellular IL-2 produc-
tion compared with normal controls' after treatment. After treatment,
the IL-2/IL-l ratio remained elevated in all groups with renal disease
compared with normal subjects. We conclude patients with renal
disease have an abnormal functional relationship between IL-l and
IL-2, characterized by increased IL-2 production per level of IL- 1,
unaffected by type or presence of renal replacement therapy.
Several investigators have suggested that in hemodialysis the
interaction between the patient's blood and the membrane of
the dialyzer might result in the generation of a variety of active
peptides or cytokines with systemic effects. This issue has been
assessed using in vitro systems and in patients with end-stage
renal disease (ESRD) treated with hemodialysis. Interleukin-l
(IL-i) synthesis has been demonstrated in an in vitro hemodi-
alysis circuit [1, 2], and after incubation of macrophages with
dialysate [3] or cuprammonium dialyzer membranes [4]. In-
creased levels of IL-i have also been demonstrated in incuba-
tion fluid from dialyzers used during clinical hemodialysis [5]
and in the plasma of patients on maintenance therapy after
completion of their treatment [6, 7]. Increased cellular produc-
tion of both IL-i [8—101 and interleukin-2 (IL-2) [10] has been
demonstrated comparing values before and after hemodialysis
in ESRD patients. These in vitro and in vivo studies support the
view that membrane related factors result in the generation of
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cytokines. These studies, however, did not address the issue of
whether such changes in interleukins were specifically related
to the uremic environment or a non-specific effect of blood-
membrane interaction. In addition, the results were not com-
pared to patients with renal disease not treated with hemodial-
ysis. Finally, time controls of normal subjects to assess the
period after hemodialysis treatments were not included in the
evaluation of these results.
Stimulation of interleukin production by macrophages and
lymphocytes has been proposed as an explanation for acute
complications such as fever, and chronic complications such as
amyloidosis, in patients treated with hemodialysis for ESRD
[11]. Therapy with IL-2 in pharmacologic doses has produced
non-specific symptoms such as chills, pruritus, nausea, vomit-
ing, edema, respiratory distress, somnolence, disorientation
and coma in patients without pre-existing renal dysfunction
[121, resembling symptoms seen in patients with chronic renal
insufficiency or ESRD treated with hemodialysis. Since there is
evidence of abnormal IL-2 production by uremic lymphocytes
[13—161, it has not been clear whether this previously reported
in vivo increase in cellular cytokine production after hemodial-
ysis treatment is secondary to the nature of the dialysate, a
cell-membrane interaction, a non-specific effect of treatment or
an intrinsic characteristic of the underlying renal disease.
Therefore we studied cellular cytokine production in patients
during treatment for ESRD with hemodialysis and continuous
ambulatory peritoneal dialysis (CAPD), compared to patients
with chronic renal insufficiency, and normal volunteers as time
controls.
Methods
Patients
Twenty-one patients with ESRD, aged 35 to 71 years, (mean
56.9 2.6 years) treated with thrice weekly chronic mainte-
nance hemodialysis, all were dialyzed with cuprophane dialyz-
ers using acetate bath. Five milliliters of whole blood was
drawn before and after a three to four hour hemodialysis
treatment. Seven patients with ESRD, treated with chronic
maintenance CAPD, aged 33 to 72 years (mean 56.7 6.5
years), had 5 ml of whole blood drawn in the morning after
drainage of the overnight peritoneal effluent, and four hours
later, after draining the morning exchange. Six patients with
chronic renal insufficiency, aged 24 to 68 years (mean 50.2 8.8
years), had 5 ml of whole blood drawn during morning clinic
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visits. In all cases, the patients' serum creatinine concentration
was greater than 8 mg/dl. No patient was treated with immu-
nosuppressive medication. Twelve normal volunteers, without
renal disease, aged 23 to 63 years (mean 38.2 3.2 years),
served as controls. In these subjects, 5 ml of whole blood was
drawn at 9 a.m. and 1 p.m.
Cytokine assays
Cellular IL-i and IL-2 production were measured by bioassay
by the method of Clemens, Morris and Gearing [17] using CRL
1445 IL-i dependent fibroblasts [18] and CTLL IL-2 dependent
lymphocytes [19], respectively, as the target cells. Briefly, 5 ml
samples of whole blood were collected in citrated glass tubes.
Mononuclear cells were separated by density centrifugation on
ficoll-hypaque [20]. The cells were washed in Eagles medium,
counted and their viability checked by trypan blue exclusion.
The cell suspension was adjusted to 5 x 106 cells/ml in medium
supplemented with 10% autologous serum, before dividing the
total cell volume into two batches. The cells were incubated at
37°C and the media replenished before pulsing one batch with
10 pg/ml lipopolysaccharide (LPS) for measurement of IL-i,
and the other with 50 g/ml phytohemagluttinin (PHA) for
measurement of IL-2, for a further 24 hours at 37°C. Following
this second incubation, the cells were centrifuged and the
supernatants harvested for use in the stimulation assay. One
hundred microliters of each supernatant were serially diluted,
and incubated with either 1 X i05 CRL or CTLL target cells in
culture for 48 hours at 37°C. The target cells were centrifuged,
replenished with fresh media and pulsed with tritiated thymi-
dine for 24 hours at 37°C. The target cells were then harvested,
and the amount of incorporated radioactivity measured in a
Beckman LS1308 scintillation counter (Beckman Instruments,
Palo Alto, California, USA). Data are expressed as tritium
incorporation in counts/minute (cpm, per culture).
Intracellular IL-2 levels were also measured simultaneously
in all subjects by an antigen capture enzyme linked immunoab-
sorbent assay (ELISA) [21] using an anti-human IL-2 solid
phase monoclonal antibody [22] (Advanced Biotechnologies,
Columbia, Maryland, USA) as both the solid phase capture
reagent and the reporter agent. The ELISA assay was used to
measure intracellular IL-2 levels following sonic disruption and
ultracentrifugation clarification of the supernatant. The samples
were compared to a standard curve, constructed by incubating
the target cells with known amounts of human IL-2 (Advanced
Biotechnologies). Data are expressed as ng/ml IL-2 (per culture
of 2.5 x 106 cells).
Data were analyzed by analysis of variance (ANOVA) to
evaluate differences between groups, and by Student's paired
t-test to evaluate differences between baseline and post-treat-
ment values. Correlations were evaluated by linear regression.
Non-parametric equivalents of these tests (Kruskal-Wallis
ANOVA, Wilcoxon matched-pair rank sum test and Spearman
rank correlation coefficient) were also performed to confirm
results. Alpha <0.05 was chosen as the level of significance.
Data are expressed as mean SEM.
All patients studied gave their informed consent. The study
was approved by the George Washington University Medical
Center Committee on Human Research.
Results
Baseline values
There was no difference in mean age between patient groups.
Patients with ESRD were older than normal subjects, but there
was no difference in mean age between normal subjects and
patients with chronic renal insufficiency. Initial mean cellular
IL-l production (baseline) was 16,400 2,700 cpm in normal
controls (Fig. 1). Initial mean cellular IL-i production in
patients with ESRD was 12,000 1300 cpm in those treated
with hemodialysis before the procedure, and 11,100 1100 cpm
in those treated with CAPD, before initiating a morning ex-
change. Mean cellular IL-l production in the patients with
chronic renal insufficiency was 10,500 1700 cpm. When the
initial mean cellular IL-l production was compared in patients
with renal disease, there were no differences between the
patient groups and normal subjects when assessed by ANOVA.
Baseline mean cellular IL-2 production was 6200 1700 cpm
in normal subjects (Fig. 2). Cellular IL-2 production was 10,700
900 cpm in those treated with hemodialysis before the
procedure, and 9000 900 cpm in those treated with CAPD,
before initiating a morning exchange. Mean cellular IL-2 pro-
duction in the patients with chronic renal insufficiency was
10,400 1800 cpm. When initial values of cellular IL-2 produc-
tion were compared, patients treated with hemodialysis had
significantly higher levels compared to normal controls when
assessed by ANOVA. There were no differences between the
mean levels of initial cellular IL-2 production in patient groups.
Mean intracellular IL-2 level was 12.9 2.8 nglml in normal
subjects at baseline. Mean intracellular IL-2 level was 35.3
3.0 nglml in patients treated with hemodialysis before the
procedure, 27.4 2.4 nglml in patients treated with CAPD
before a morning exchange, and 40.3 8.5 nglml in patients
with chronic renal insufficiency. There were no differences
between means in patient groups, but all patient groups were
significantly increased compared to the mean value of normal
subjects. In the normal subjects, paired intracellular IL-2 levels
at baseline evaluation correlated with cellular IL-2 production
(r = 0.95, P < 0.001). In the 34 subjects with renal disease
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Fig. 1. Baseline cellular IL-i production in patient groups. All baseline
IL-I values are in cpm, and are illustrated in black. There were no
significant differences between group means.
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elevated (0.82 0.06) in patients treated with CAPD and was
highest (1.1 0.1) when evaluated in patients with chronic
renal insufficiency, untreated with renal replacement therapy.
The ratio was significantly elevated (P < 0.01) in all groups of
patients with renal disease compared to the normal subjects
when evaluated by ANOVA. No differences were detected in
this value when non-dialyzed patients with chronic renal insuf-
ficiency were compared to patients with ESRD, treated with
either hemodialysis or CAPD as maintenance renal replacement
therapy.
Effect of dialysis
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Fig. 2. Baseline cellular IL-2 production in patient groups. All baseline
IL-2 values are in cpm, and are illustrated in gray. Mean IL-2 produc-
tion was greater (P < 0.05) in hemodialysis patients compared to normal
controls, but similar in all patient groups. * P < 0.05, hemodialysis vs.
normal, ANOVA.
(chronic renal insufficiency, hemodialysis and CAPD groups),
paired intracellular IL-2 levels at baseline evaluation correlated
with cellular IL-2 production (r 0.60, P <0.0002). In the 28
ESRD patients (hemodialysis and CAPD), initial cellular IL-2
production and intracellular IL-2 levels were correlated as well
(r = 0.60, P < 0.0007). In patients treated with hemodialysis
and CAPD, there were also significant correlations between
intracellular IL-2 levels and cellular IL-2 production before
treatment (hemodialysis, r 0.92, P <0.0001, and CAPD, r =
0.83, P < 0.02).
Since IL-I may affect IL-2 production by lymphocytes,
paired values of cellular cytokine production were compared in
normal subjects, and patients with renal disease. The correla-
tion of baseline mean cellular IL-I and 11-2 production in all
subjects is illustrated in Figure 3. In both normal subjects, and
patients with renal disease, a highly significant correlation can
be demonstrated between these values. IL-I and IL-2 produc-
tion were correlated in normal volunteers (r = 0.90, P <
0.0001). In the 34 subjects with renal disease (chronic renal
insufficiency, hemodialysis and CAPD groups), IL-l and IL-2
production at baseline evaluation were correlated (r = 0.67, P <
0.0001). Although the correlation coeficients (slopes) were not
significantly different, the y-intercepts of the two regression
lines were, suggesting different set points for IL-2 production in
the two populations. In the 28 ESRD patients (hemodialysis and
CAPD), initial cellular IL-i and IL-2 production were corre-
lated (r = 0.67, P < 0.0001). The y-intercept in this regression
line was also different from normal controls'. In patients treated
with hemodialysis and CAPD, there were also significant cor-
relations between IL-l and IL-2 production before treatment
(hemodialysis, r = 0.75, P < 0.0001, and CAPD, r = 0.75, P <
0.05).
The relationship between the two cytokines was also ana-
lyzed by comparing the ratios of cellular IL-2 and IL-I produc-
tion. The mean ratios of initial cellular IL-2 and IL-I production
in these populations are illustrated in Figure 4. The ratio was
0.35 0.06 in normal controls. This ratio was significantly
elevated in patients treated with hemodialysis, 0.98 0.07,
when compared to the normal subjects. The ratio was similarly
There were no differences in mean cellular IL-l production in
normal time controls when reassessed after a four hour period
(IL-i production 16,400 2,700 vs. 16,400 2,500 cpm; Fig.
5). Cellular IL-i production was increased after both hemodi-
alysis (12,000 1,300 vs. 18,200 2,900 cpm, 51.7%, P <
0.007), and CAPD treatments (11,200 1,100 vs. 16,000
1,800 cpm, 42.9%, P < 0.002). There were no differences
between mean post-treatment (experimental) cellular IL-l pro-
duction levels in the groups.
Cellular IL-2 production was unchanged in normal time
controls when the initial values were compared with values
assessed four hours later (Fig. 6). In contradistinction to the
control group, both hemodialysis and CAPD treatments re-
sulted in increased mean cellular IL-2 production (10,700 900
vs. 16,100 2,900 cpm, 50.5%, P < 0.015 and 9,000 900 vs.
12,000 1000 cpm, 33.3%, P < 0.0008, respectively). The
hemodialysis group had higher mean post-treatment (experi-
mental) cellular IL-2 production compared to the normal con-
trols, when the groups were assessed by ANOVA.
Mean intracellular IL-2 level was 13.0 3.0 ng/ml in normal
subjects after four hours, unchanged from baseline evaluation.
Mean intracellular IL-2 levels were significantly elevated, 46.2
10.1 ng/ml (30.9%, P < 0.03) in patients treated with
hemodialysis after the procedure, and 35.4 3.0 nglml in
patients treated with CAPD after a morning exchange (29.3%, P
<0.0007), compared to their respective baseline values. There
were no differences between means in patient groups; however,
intracellular IL-2 levels were greater in patients treated with
hemodialysis compared to normal subjects. In the normal
subjects, cellular IL-2 production and intracellular IL-2 levels
were correlated (r = 0.96, P < 0.0001) when assessed after four
hours. In the 28 ESRD patients (hemodialysis and CAPD),
cellular IL-2 production and intracellular IL-2 levels were
correlated (r = 0.98, P < 0.0001) after treatment. In patients
treated with hemodialysis and CAPD, there were also signifi-
cant correlations between intracellular IL-2 levels and cellular
IL-2 production after treatment (hemodialysis, r = 0.98, P <
0.001, and CAPD, r = 0.99, P <0.0001).
In both normal subjects and patients with renal disease,
significant correlations were demonstrated between post-treat-
ment mean cellular IL-l and IL-2 production. IL-i and IL-2
production were correlated in normal volunteers (r = 0.90, P <
0.000 1) at four hours. In the 28 ESRD patients, post-treatment
cellular IL-i and IL-2 production were correlated (r =0.89, P <
0.0001). In patients treated with hemodialysis and CAPD, there
were also significant correlations between IL-i and IL-2 pro-
duction before treatment (hemodialysis, r = 0.90, P < 0.0001
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Fig. 3. Baseline cellular IL-i and IL-2
production in normal subjects and patients
40000 with renal disease. Subjects with renal disease
are depicted by black diamonds. Normal
subjects are depicted by open squares.
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Fig. 4. Analysis of baseline IL-2/IL-I ratio in patient groups. All
patient groups had significantly elevated ratios compared to values in
normal subjects. Symbol is (El) pre-IL-2/IL-1.
post-treatment, and CAPD, r = 0.93, P < 0.002 post-treat-
ment).
The ratio of cellular IL-2 and IL-I production was 0.35 0.06
at the four hour assessment period in normal time control
subjects, unchanged from the baseline value (Fig. 7). This ratio
was significantly elevated (P < 0.01) in patients with ESRD,
whether treated with hemodialysis (0.95 0.06 after treat-
ment), or CAPD (0.77 0.04 after treatment) when compared
to the normal subjects. There was no difference in the ratio
between groups of patients with ESRD when compared by
ANOVA.
Discussion
There is growing interest in the molecular mechanisms of
immune regulation and their role in human diseases. This
Fig. 5. Baseline and post-treatment cellular IL-I production in normal
subjects and patients with ESRD. All baseline IL-I values are in cpm,
and are illustrated in black. All post-treatment values are illustrated by
gray bars. There was a significant increase in post-treatment values in
both groups of ESRD patients. * P < 0.01, ** P < 0.002, baseline vs.
post-treatment.
interest has focused on cytokine activity, the mechanisms
which stimulate their production and the consequences of
excessive cytokine production. The two most studied cytokines
are IL- 1 and IL-2. IL- 1, a product of macrophages and mono-
cytes, is the most pleiomorphic of the cytokines and its produc-
tion affects not only cells of the immune system, but other
cellular activities such as fibroblast proliferation, acute phase
reactant release from hepatocytes and bone resorption [23].
Although the release of this cytokine has potentially useful
consequences, such as a role in wound healing and as a
stimulator of hematopoiesis [24], immunologically its major
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Fig. 6. Baseline and post-treatment cellular IL-2 production in pa-
tients with ESRD. All baseline IL-2 values are in cpm, and are
illustrated in black. All post-treatment values are illustrated by gray
bars. There was a significant increase in post-treatment values in both
groups of ESRD patients, * P < 0.02, ** P < 0.001, baseline vs.
post-treatment. Post-treatment IL-2 production was greater in hemodi-
alysis patients compared to 4 hour values in normal controls, # P <
0.05, ANOVA, but was similar in both patient groups.
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Fig. 7. Analysis of post-treatment JL-2/JL-l ratio (E') in patient
groups. Both patient groups had significantly elevated ratios compared
to values in normal subjects.
effect is to augment antigen-specific activity such as the release
of IL-2 [25] and B cell mitogenesis [26].
Release of IL-2 further activates immunological reactivity by
stimulating T cell proliferation and the clonal expansion of
antigen-specific T cells [27]. In addition, IL-2 can stimulate
phagocytosis and antibody production [28, 29]. All of these
events are activators of the immune system and as such have
received interest from the transplantation community. In-
creases in IL-l [30] and IL-2 [30, 31] levels have been impli-
cated as indicators of active renal allograft rejection.
Reports from different laboratories regarding cytokine pro-
duction in patients with renal disease have been conflicting.
Blumenstein et al [81 found diminished cellular IL-i production
in supernatants, but increased cytopiasmic IL-I levels in pa-
tients treated with hemodialysis. Normal [31, 32] and dimin-
ished [13—16] cellular IL-2 production capacity have been
reported in hemodialysis patients, while normal IL-2 produc-
tion has been reported in peripheral blood mononuclear cells
from patients with ESRD treated with CAPD [13]. In addition,
ii vestigators have suggested a "preactivation" of T cells in
h rmodialyzed patients before treatment, characterized by in-
c eased responses to exogenous IL-2, suggestive of a change in
the membrane receptor for this cytokine [16]. Yousefi et a! [32]
showed no difference in stimulated mononuclear cell IL-2
production between normal controls and patients with ESRD
treated with hemodialysis, but demonstrated an increased level
of interferon-gamma production in the patients. These authors
speculated that such cytokine production could enhance the
secretion of IL-i, and perhaps play a role in the generation of
hemodialytic complications.
Previous studies have demonstrated increased interleukin
production during hemodialysis [6—10]. It had been concluded
that stimulation of the interleukin system was a biocompatibil-
ity phenomenon. None of these studies employed a time control
for the normal subjects' response. Since circulating interleukin
levels may be affected by fluid losses during ultrafiltration in
dialysis, we chose to use indices of cellular cytokine production
and intracellular IL-2 levels as markers of possible stimulation
by renal replacement therapy.
Our studies demonstrate an abnormal and hyperreactive
relationship between cellular IL-2 and IL-l production in
patients with renal disease. Time control studies demonstrate
the stability of our measurements of cellular cytokine produc-
tion in normal subjects. Repeat studies in patients with renal
disease (not shown) demonstrate the reproducibility of the
interleukin determinations.
When patient groups before treatment are compared to
normal subjects, there are no differences in cellular IL-l pro-
duction capacity, but patients treated with hemodialysis have
increased cellular IL-2 production. All patient groups had
greater intracellular IL-2 levels than normal subjects when
evaluated before treatment. Isolated measurements of IL-! and
IL-2 production and levels, however, are difficult to interpret
due to the wide variation in values observed in patients and
normal subjects. However, when the ratio of IL-i and IL-2
production or their correlation is studied, it becomes apparent
that there is a significant and different relationship between
these two parameters in normal subjects and patients with renal
disease.
We have therefore used the ratio of cellular IL-2 and IL- 1
production capacity as an index of the normal relationship
between the cytokines. Before treatment, however, an abnor-
mal relationship between cellular IL-2 and IL-I production is
demonstrated by the difference between the ratios of the
production of these cytokines in patients with renal disease,
compared with normal subjects (Figs. 4 and 7). Patients with
chronic renal insufficiency or ESRD treated with hemodialysis
or CAPD have greater production of IL-2 per IL- 1 level than
normal subjects (Fig. 3). The similarity of the ratio in patients
with chronic renal insufficiency to that in patients with ESRD
suggests that this is not an effect of long-term renal replacement
therapy, but an abnormality intimately associated with renal
disease. Neither long-term hemodialysis or CAPD treatment
restores this disordered relationship to normal.
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We have demonstrated that both hemodialysis and CAPD
treatments result in increased capacity for cellular cytokine
production compared to that in normal time controls. The
similarity of the response in the two groups of patients treated
for ESRD suggests that this is not a biocompatibility effect,
related to the particular membrane employed in the dialyzer
used for hemodialysis, or a finding secondary to the change in
immune cell subsets noted after hemodialysis [33]. An alterna-
tive explanation for these findings is the possibility that renal
replacement therapy enhances the capacity of cellular cytokine
production by improving the uremic milieu [16] as a conse-
quence of the dialytic therapy. This hypothesis does not,
however, explain the increased baseline cellular IL-2 produc-
tion capacity in patients treated with chronic hemodialysis, the
abnormal relationship noted before treatment in the ESRD
patients, or abnormalities in patients with chronic renal insuf-
ficiency. The hyperreactive, "uremic" interleukin system re-
sponds with greater IL-2 production for a given level of cellular
IL-i production in treated and untreated patients with renal
disease. This phenomenon may be a consequence of changes in
cytokine receptors on immune cells [14].
Since IL-2 therapy in pharmacologic doses has been noted to
produce symptoms that resemble complications of hemodialy-
sis, it is interesting to speculate that treatment effects may
contribute to chronic stimulation of cytokine production, and
the perpetuation of uremic symptoms in patients treated with
renal replacement therapy. Perhaps this long-term abnormality
in cellular cytokine production is associated with the failure to
rehabilitate patients with ESRD [34, 35] treated with various
forms of dialysis.
Renal transplant patients are often hemodialyzed prior to or
immediately after transplantation. Activation of cellular cyto-
kine production may possibly lead to activation or hyperactivity
of patients' immune systems prior to transplantation, perhaps
leading to increased prevalence of rejection and greater diffi-
culty in the management of immunosuppressive therapy. Re-
cent studies have suggested a role for the immune system in the
progression of established renal disease [361. Our studies dem-
onstrating an activated cytokine system in uremic patients
would support this view.
The role of cellular cytokine production in mediating short
and long-term complications in patients with chronic renal
insufficiency and end-stage renal disease deserves further in-
vestigation.
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